House Rx Hearing Topics Include Generics, DTC And Antihistamine OTC Switch
Executive Summary
A House subcommittee will examine FDA's legal authority to switch an Rx drug over-the-counter without the sponsor's consent during a June 13 hearing.
You may also be interested in...
Aventis Studying Allegra For Dermatitis And Asthma, Firm Tells OTC Cmte.
Aventis is pursuing an atopic dermatitis indication for the antihistamine Allegra, Senior VP-Medical & Regulatory Francois Nader, MD, told the FDA OTC switch advisory committee May 11.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials